Immune checkpoint inhibitors or targeted therapy by mismatch repair status in endometrial cancer: a meta-analysis

Immune checkpoint inhibitors or targeted therapy by mismatch repair status in endometrial cancer: a meta-analysis

Objective This study evaluated the benefits of immune checkpoint inhibitors (ICIs) and/or targeted therapies in mismatch repair-deficient (dMMR) and mismatch repair-proficient (pMMR) patients with advanced or recurrent endometrial cancer (EC) via network meta-analysis.Methods English databases were...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yi Tang, Yan Chen, Ting Zeng, Kui Huang, Jing Zhao, Pu Zhang, Chuqiang Shu
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2025-12-01
Series:	Future Science OA
Subjects:	Endometrial cancer mismatch repair survival immune checkpoint inhibitors targeted therapies meta-analysis
Online Access:	https://www.tandfonline.com/doi/10.1080/20565623.2025.2541517
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy and safety of immune checkpoint inhibitors for advanced or recurrent endometrial cancer: a systematic review and network meta-analysis
by: Danxue Huang, et al.
Published: (2024-10-01)

Case Report: Medullary carcinoma of the pancreas with MLH1 promoter hypermethylation, induced deficient mismatch repair, successfully treated with an immune checkpoint inhibitor
by: Koushiro Ohtsubo, et al.
Published: (2025-03-01)

The impact of mismatch repair (MMR), p53, and LCAM-1 immunohistochemical expression on prognosis in low-risk endometrial cancer
by: Şener Gezer, et al.
Published: (2025-06-01)

A Prospective Study to Evaluate the Prevalence of Microsatellite Instability in Endometrial Carcinoma by using Immunohistochemistry for Mismatch Repair Proteins as a Surrogate Marker
by: Prithviraj K. Solanki, et al.

Durable Clinical Benefit after Dual Checkpoint Inhibition and Single-agent Nivolumab Following Pembrolizumab Failure in Mismatch Repair-deficient Colon Cancer
by: Yat-Fung Chow, et al.
Published: (2023-10-01)

This is not Lynch syndrome: lessons from misattributed diagnoses in constitutional mismatch repair deficiency
by: A.H. Mohammad, et al.
Published: (2024-12-01)

Sustained disease control with pembrolizumab-lenvatinib in a patient with heavily pre-treated recurrent endometrial carcinoma: a case report
by: Alessia Lancianese, et al.
Published: (2025-06-01)

Advancing endometrial cancer treatment: exploring immunotherapy and tyrosine kinase inhibitors through clinical cases
by: Vanda Salutari
Published: (2025-06-01)

Case Report: Lasting complete response to pembrolizumab in mismatch repair-deficient cardiac sarcoma: a genomic characterization
by: Daniela A. Ferraro, et al.
Published: (2025-04-01)

The efficiency of neoadjuvant chemotherapy in colon cancer with mismatch repair deficiency
by: Wu Yunlong, et al.
Published: (2023-02-01)

The neoadjuvant immunotherapy for non-metastatic mismatch repair-deficient colorectal cancer: a systematic review
by: Hong-Xia Cui, et al.
Published: (2025-05-01)

Clinical Implications of Mismatch Repair Deficiency in Pancreatic Ductal Adenocarcinoma
by: Zachary Kaplan, et al.
Published: (2025-05-01)

Comparative efficacy and safety of transarterial chemoembolization combined with tyrosine kinase inhibitors and immune checkpoint inhibitors versus tyrosine kinase inhibitors and immune checkpoint inhibitors alone in advanced hepatocellular carcinoma: a systematic review and meta-analysis
by: Hengyu Tian, et al.
Published: (2025-04-01)

Prognostic value of inflammatory markers NLR, PLR, LMR, dNLR, ANC in melanoma patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review
by: Yan Ou, et al.
Published: (2024-10-01)

Generation of DNA nanocircles containing mismatched bases
by: Yu Xiao, et al.
Published: (2011-10-01)

The prognostic implication of polymerase epsilon-mutated endometrial cancer
by: Kai-Hung Wang, et al.
Published: (2025-04-01)

Risk factors for checkpoint inhibitor pneumonitis in lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
by: Xiaoqing Zhou, et al.
Published: (2025-05-01)

Immune checkpoint inhibitor-related myocarditis during DUO-E regimen for endometrial cancer: The first case report in gynecologic oncology
by: Eri Yamabe, et al.
Published: (2025-10-01)

Programmed death‐ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2‐negative status
by: Lei Wang, et al.
Published: (2018-06-01)

Comparative Efficacy of Immune Checkpoint Inhibitors and Therapeutic Vaccines in Solid Tumors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Rasha Babiker, et al.
Published: (2025-04-01)

Molecular Classification Guides Fertility-Sparing Treatment for Endometrial Cancer and Atypical Hyperplasia Patients
by: Yiqin Wang, et al.
Published: (2025-05-01)

Microsatellite instability in endometrial cancer: the role of diagnostic methods and their clinical application. Expert consensus
by: A. S. Tyulyandina, et al.
Published: (2023-05-01)

An Excellent Clinical and Radiological Response Pattern to Pembrolizumab in a Patient With Metastatic Adrenocortical Carcinoma and Lynch Syndrome
by: Yuki Shimozawa, et al.
Published: (2025-07-01)

Immune checkpoint inhibitor‐related type 1 diabetes incidence, risk, and survival association
by: Fumika Kamitani, et al.
Published: (2025-02-01)

The efficacy and safety of neoadjuvant and adjuvant chemo(radio)therapy combined with surgery in patients with locally advanced rectal cancer harboring defective mismatch repair system: a large-scale multicenter propensity score analysis
by: Huan-Huan Wang, et al.
Published: (2025-07-01)

The DNA mismatch repair protein, MSH6 is a novel regulator of PD-L1 expression
by: Kirsten Brooksbank, et al.
Published: (2025-09-01)

Action-At-A-Distance in DNA Mismatch Repair: Mechanistic Insights and Models for How DNA and Repair Proteins Facilitate Long-Range Communication
by: Bryce W. Collingwood, et al.
Published: (2024-11-01)

Does Pre-Existing Chronic Obstructive Pulmonary Disease Increase the Risk of Checkpoint Inhibitor Pneumonitis in Advanced/Metastatic Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors?
by: David Spillane, et al.
Published: (2025-04-01)

Cerebral developmental venous anomalies in children with mismatch repair deficiency
by: Buket Kara, et al.
Published: (2022-12-01)

Comprehensive Analysis of Oncogenic Somatic Alterations of Mismatch Repair Gene in Breast Cancer Patients
by: Yin Yan, et al.
Published: (2025-04-01)

A Delayed Presentation of Immune Checkpoint Inhibitor Colitis
by: Alicia Nahhas, et al.
Published: (2025-06-01)

Study of Immunohistochemical Expression Patterns of Mismatch Repair Proteins in Endometrial Carcinoma and Endometrial Hyperplasia: An Institutional Study
by: Belani Vaishali Tulsidas, et al.

Predicting immunotherapy efficacy in endometrial cancer: focus on the tumor microenvironment
by: Liubov A. Tashireva, et al.
Published: (2025-01-01)

Spontaneous regression of advanced transverse colon cancer with deficient mismatch repair: a case report
by: Shinnosuke Harata, et al.
Published: (2023-04-01)

Impact of Immune Checkpoint Inhibitors and Local Radical Treatment on Survival Outcomes in Synchronous Oligometastatic NSCLC
by: Mandy Jongbloed, MD, et al.
Published: (2025-03-01)

Analyzing pathogenic variants in mismatch repair genes: personalized prevention strategies for lynch syndrome in Chinese families
by: Xiufang Wang, et al.
Published: (2025-03-01)

Immune checkpoint inhibitors in cancer patients with autoimmune disease: Safety and efficacy
by: Jiayuan Le, et al.
Published: (2025-12-01)

Negative Immune Checkpoint Inhibitors
by: Magda Drewniak-Świtalska, et al.
Published: (2025-05-01)

Spleen Volume Dynamics and Survival Outcomes in HCC Patients Undergoing Immune Checkpoint Inhibitors: A Retrospective Analysis
by: Fu X, et al.
Published: (2025-05-01)

Efficacy and Safety of Immune Checkpoint Inhibitors for Cervical Cancer: A Systematic Review and Meta-Analysis
by: Xian Zhang, et al.
Published: (2024-08-01)